<DOC>
	<DOCNO>NCT00355888</DOCNO>
	<brief_summary>The purpose study determine whether MBP-426 ( liposomal oxaliplatin suspension injection ) safe effective treatment advance metastatic solid tumor .</brief_summary>
	<brief_title>Safety Study MBP-426 ( Liposomal Oxaliplatin Suspension Injection ) Treat Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>Study Phase 1 Study Type ( Interventional/Observational ) Interventional Study Design Purpose : Treatment Allocation : Nonrandomized trial Masking : Open Control : Dose Comparison Assignment : Single Group Endpoint : Safety/Efficacy</detailed_description>
	<criteria>Pathologicallyconfirmed malignancy locally advance metastatic solid tumor refractory standard therapy conventional therapy reliably effective effective therapy available 18 year age old ECOG Performance Status 0 , 1 , 2 Adequate clinical laboratory value : absolute neutrophil count great equal 1500 cells/microliter platelet great equal 100,000 cells/microliter serum creatinine less equal 1.5 x upper limit normal ( ULN ) institution creatinine clearance ( calculate ) &gt; 60 mL/min ( use CockcroftGault equation ) bilirubin less equal 1.5 x ULN alanine transaminase ( ALT ) aspartate transaminase ( AST ) less equal 2.5 x ULN ( patient know liver metastasis may 5 time ULN AST ALT level ) . Ability cooperate treatment followup schedule Negative pregnancy test use least one form contraception approve Investigator prior study entry female patient childbearing potential male patient female partner childbearing potential Measurable disease define RECIST criterion nonmeasurable disease Patients know brain metastasis may include long clinically stable one month , receive dexamethasone Ability maintain central intravenous access ( e.g . PICC , Groshong , Hickman line ) Signed informed consent prior start study specific procedure Received previous anticancer chemotherapy , immunotherapy , radiotherapy investigational therapy 4 week ( 6 week nitrosoureas mitomycin C ) prior study entry Received extensive prior radiotherapy 30 % bone marrow reserve , prior bone marrow/stem cell transplantation Any concomitant condition could compromise objective study patient 's compliance Pregnant lactate woman Current malignancies another type , exception adequately treat situ cervical cancer basal cell skin cancer demonstrate evidence disease 5 year Clinically evident HIV , HBV , HCV infection Hematologic malignancy Documented known bleed disorder Requirements therapeutic anticoagulation increase INR aPTT normal range ( low dose deep vein thrombosis [ DVT ] line prophylaxis allow ) Congestive heart failure Greater Grade 1 peripheral neuropathy accord National Cancer Institute 's Common Terminology Criteria Adverse Events v3.0 ( CTCAE version 3.0 ) History allergic reaction platinumbased liposomal agent Creatinine clearance ( calculate ) less equal 60 mL/min ( use CockcroftGault equation ) Receiving initiate treatment investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced Metastatic Solid Tumor</keyword>
</DOC>